Sabrina Ravaglia

TL;DR: Five patients who had Guillain–Barre syndrome 5 to 10 days after the onset of Covid-19 are described and three had severe weakness and an axonal pattern on electr...

TL;DR: In view of its effect in improving established paclitaxel- and cisplatin-neuropathy, ALC testing in preventing progression or revert symptoms during neurotoxic chemotherapy is recommended.

TL;DR: An increased incidence of GBS is shown during the COVID-19 outbreak in northern Italy, supporting a pathogenic link and seems to be more severe than non-COVID- 19 GBS, although it is likely that in some patients the systemic impairment due to CO VID-19 might have contributed to the severity of the whole clinical picture.

TL;DR: A high prevalence of “atypical variants” was found in this series of postinfectious ADEM patients, with site-restricted damage or additional peripheral nervous system (PNS) involvement, except for some patient subgroups.

TL;DR: Results, obtained in a large case series on therapy, indicate a favourable effect of ERT therapy, even in more advanced stage of the disease.